Show simple item record

In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.

dc.contributor.authorRoblin, P M
dc.contributor.authorReznik, T
dc.contributor.authorKutlin, A
dc.contributor.authorHammerschlag, M R
dc.date.accessioned2023-06-30T16:57:41Z
dc.date.available2023-06-30T16:57:41Z
dc.date.issued1999-11
dc.identifier.citationRoblin PM, Reznik T, Kutlin A, Hammerschlag MR. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother. 1999 Nov;43(11):2806-7. doi: 10.1128/AAC.43.11.2806. PMID: 10543770; PMCID: PMC89566.en_US
dc.identifier.issn0066-4804
dc.identifier.pmid10543770
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10348
dc.description.abstractWe compared the in vitro activity of gemifloxacin, a new quinolone antibiotic, to the activities of levofloxacin, moxifloxacin, trovafloxacin, erythromycin, and doxycycline against 20 isolates of Chlamydia pneumoniae. Gemifloxacin was the most active quinolone tested, with a MIC at which 90% of the isolates are inhibited and a minimal bactericidal concentration at which 90% of strains tested are killed of 0.25 microg/ml, but this activity was less than those of doxycycline and erythromycin.
dc.language.isoenen_US
dc.relation.urlhttps://journals.asm.org/doi/epub/10.1128/aac.43.11.2806en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleIn vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAntimicrobial agents and chemotherapyen_US
dc.source.volume43
dc.source.issue11
dc.source.beginpage2806
dc.source.endpage7
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-06-30T16:57:42Z
html.description.abstractWe compared the in vitro activity of gemifloxacin, a new quinolone antibiotic, to the activities of levofloxacin, moxifloxacin, trovafloxacin, erythromycin, and doxycycline against 20 isolates of Chlamydia pneumoniae. Gemifloxacin was the most active quinolone tested, with a MIC at which 90% of the isolates are inhibited and a minimal bactericidal concentration at which 90% of strains tested are killed of 0.25 microg/ml, but this activity was less than those of doxycycline and erythromycin.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAntimicrobial agents and chemotherapy
dc.identifier.issue11en_US


Files in this item

Thumbnail
Name:
aac.43.11.2806.pdf
Size:
35.84Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International